IMTX logo

IMTX
Immatics N.V

949
Mkt Cap
$1.5B
Volume
5,474.00
52W High
$12.41
52W Low
$4.62
PE Ratio
-5.66
IMTX Fundamentals
Price
$11.02
Prev Close
$11.17
Open
$10.86
50D MA
$10.50
Beta
1.27
Avg. Volume
318,388.08
EPS (Annual)
-$1.81
P/B
2.91
Rev/Employee
$133,837.70
$751.81
Loading...
Loading...
News
all
press releases
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
More News
News Placeholder
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
Zacks·8d ago
News Placeholder
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Zacks·8d ago
News Placeholder
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
Zacks·8d ago
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -15.99% and -45.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·9d ago
News Placeholder
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up
Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.
Zacks·9d ago
News Placeholder
Immatics (IMTX) to Release Quarterly Earnings on Tuesday
Immatics (NASDAQ:IMTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-immatics-stock...
MarketBeat·10d ago
News Placeholder
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -14.82% and +2.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Immatics (NASDAQ:IMTX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered Immatics from a 'hold' rating to a 'sell' rating in a report on Saturday...
MarketBeat·13d ago
<
1
2
...
>

Latest IMTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.